CPRX - Catalyst Pharmaceuticals jumps 2% on prelim Q4 and FY 2022 reports

• Catalyst Pharmaceuticals ( NASDAQ: CPRX ) provided preliminary Q4 and FY reports, expects FY revenue to be $214M, representing 52% Y/Y growth.
• Expects Q4 total revenues to be ~$61M, ~61% Y/Y growth.
• Forecasts 2023 total revenues of between $375M-385M, representing 75-80% Y/Y growth.
• • 2023 FIRDAPSE net revenues estimated at $245M-255M.
  • 2023 FYCOMPA net revenues estimated at $130M - 11 months
  • FYCOMPA business unit integration expected to be completed by Mid-Year 2023
  • Ended 2022 with ~$298M in cash and cash equivalents.

For further details see: